Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Noxxon Pharma has started a Phase I trial to investigate NOX-H94 as a treatment for anemia of chronic disease.
Subscribe to our email newsletter
NOX-H94 is a Spiegelmer that targets peptide hormone hepcidin, the key regulator of iron metabolism.
The trial aims to investigate the tolerability and safety of NOX-H94 with an objective to test pharmacokinetic/pharmacodynamic responses to the compound.
In the trial, the patients will be initially given escalating single doses of NOX-H94 and will then be tested with multiple doses.
Both the intravenous and sub-cutaneous routes of administration will be tested.
Noxxon CEO Iain Buchanan said preliminary data from the study indicates NOX-H94 is safe and well tolerated.